LIQUID BIOPSY IN MYELOMA TO INFORM OUTCOME AND TREATMENT DECISIONS

Basic Information

Funding Cycle : 2021-2022
Name : Jens Lohr
Type of Award : Translational Research Award
Home Institution : Dana-Farber Cancer Institute
Host Institution : N/A

Description

The proposal aims to revolutionize the assessment and treatment of multiple myeloma (MM) by introducing liquid biopsy techniques as alternatives to invasive bone marrow biopsies. Despite recent therapeutic advances, MM remains incurable, necessitating frequent biopsies for optimal treatment. However, standard bone marrow biopsies have limitations, such as representing only a single site and missing dynamic changes during treatment. The proposal suggests using circulating multiple myeloma cells (CMMCs) and cell-free myeloma DNA obtained from blood draws to provide more comprehensive insights into MM’s molecular dynamics and genomic evolution. Specific aims include using cell-free DNA to assess treatment success and predict outcomes and determining minimal residual disease (MRD) through liquid biopsy. Success would establish liquid biopsy as an independent marker for disease burden and outcome, revolutionizing MM management and potentially impacting various other malignancies.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Login
See All of the Member Benefits
Become a Member Today

Stay updated on our Events